John Thompson & Jeff Harrison: Procurement roundtable seeks to support Black-owned businesses
Investing in Black business enterprises isn’t just the right thing to do, it’s smart business.
Investing in Black business enterprises isn’t just the right thing to do, it’s smart business.
The sectors in central Indiana account for one out of every 10 jobs here, or 164,144 workers, and the jobs pay an average of $77,229, according to the report commissioned by BioCrossroads.
Roche Diagnostics is requiring COVID-19 vaccinations for all 8,000 people in its U.S. workforce, including about 4,500 in Indianapolis. Employees will have until Nov. 15 to get fully vaccinated, or will be terminated, the company said in a statement.
Two former job applicants, aged 55 and 49, filed a proposed class-action lawsuit in U.S. District Court in Indianapolis on Wednesday, accusing the Indianapolis-based drug maker of age discrimination.
According to a report by the Indiana Economic Development Corp., the Hoosier state ranks second nationally for worldwide life sciences exports and among the top five states for life sciences industry jobs.
The engine maker confirmed Wednesday it is pushing its return-to-office timeline to early next year as COVID-19 infections and hospitalizations surge in Indiana and the nation.
One day a week, students work (and learn) at companies as close as a few minutes away, or as far as Carmel.
Fueled with a $36 million Lilly Endowment Inc. grant, the Central Indiana Corporate Partnership has launched AnalytiXIN to promote innovations in data science throughout Indiana.
Two new supplier-diversity programs are launching in Indianapolis as local companies and other organizations try to make good on their equity promises from last year.
Ersal Ozdemir, founder of Keystone Group and the Indy Eleven professional soccer team, is pressing ahead and betting big on our city’s future.
Lilly’s BLAZE-1 study examined antibody therapy engineered from one of the first individuals in the United States to recover from COVID and was specifically designed to attack the virus that causes it, SARS-CoV-2.
Eli Lilly’s therapy has been shown to be highly effective against the delta variant, which is now the dominant strain of the coronavirus in the United States.
The drugmaker’s COVID-19 treatment is back on the market after a two-month suspension, but the question is whether Lilly can grab market share from now-dominant Regeneron Pharmaceuticals.
A panel of health care experts in Indianapolis on Friday endorsed President Biden’s order that all businesses with more than 100 employees require their workers to be immunized or face weekly testing.
The Catholic hospital system is stepping up its vaccination mandate for employees, telling them they must get their first dose by Oct. 15 and their second dose by Nov. 15, or submit to weekly testing.
Exelead Inc., with headquarters at 6925 Guion Road on the northwest side, said it has manufactured and shipped tens of millions of doses of the Pfizer-BioNTech vaccine in recent months and is expanding its facilities.
The company said Tuesday that the treatment, known as AZD7442, would be the first long-acting antibody combination to receive an emergency authorization for COVID-19 prevention.
“A cut [in drug prices] like is being proposed would have about a 40% reduction in our U.S. revenues,” Lilly CEO David Ricks said in a television interview this week with Gerry Dick on Inside Indiana Business, a division of IBJ Media.
The company offers full creative design, illustration, writing, digital strategy, web design and web development, in addition to PR and community relations.
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.